Bionano Genomics Q3 revenue rises on optical genome mapping adoption
BNGO•Bionano Genomics said third-quarter revenue rose 12% year over year to $8.3 million, while gross margin increased to 48% from 46%. Revenue was below the $8.44 million consensus estimate, and the company reiterated full-year 2026 revenue guidance of $31 million to $33 million.
1. Quarterly results
Bionano Genomics reported third-quarter revenue of $8.3 million, up 12% year over year and below the $8.44 million consensus estimate. Gross margin rose to 48% from 46% a year earlier, while operating expenses fell 12% to $10.5 million.
2. Outlook and adoption
The company reiterated its full-year 2026 revenue guidance of $31 million to $33 million. It cited optical genome mapping adoption in clinical and commercial settings, reimbursement and regulatory progress, and new peer-reviewed studies as supporting factors, and said momentum positions it for sustained growth in 2027 and beyond.
